Latest Manufacturing News

Page 16 of 335
Aurora Labs has secured $6 million to expand production of its additively manufactured turbojet systems, with Walkinshaw Group joining the placement as a strategic investor. The raise will fund equipment, production infrastructure and the company’s push from early deliveries towards scaled commercial manufacturing.
Victor Sage
Victor Sage
28 Oct 2026
Archer Materials has moved its IonQ relationship into early commercial activity and advanced its Biochip towards external testing, but its graphene spin qubit demonstration is taking longer than expected. The company ended September with $A13.0 million in cash and an estimated 4.68 quarters of funding at its quarterly operating burn.
Victor Sage
Victor Sage
28 Oct 2026
Electrovaya will invest approximately A$2.0 million in Janus Electric through a proposed placement, while Janus has placed initial battery orders worth about A$37.5 million for its North American truck programme. The investment remains subject to completion conditions, and the battery orders depend on agreed delivery schedules.
Maxwell Dee
Maxwell Dee
28 Oct 2026
SHAPE Australia has lifted FY27 project wins above $1.4 billion after securing an approximately $800 million DigiCo data centre contract, with the project expected to add about $200 million of revenue in each of FY27 and FY28. The award comes alongside stronger modular revenue, a new Western Australian facility and a quarter-end backlog up 21%.
Victor Sage
Victor Sage
28 Oct 2026
Big River Industries has carried its FY26 recovery into the new financial year, reporting 10.5% first-quarter revenue growth and a further lift in gross margin. The building-products group says its growth initiatives support above-market expansion, while a strategic review remains unresolved.
Victor Sage
Victor Sage
28 Oct 2026
XPON Technologies has completed the Datisan disposal for $8.1 million in initial cash, repaid its short-term loan and redirected its attention to Wondaris and applied AI acquisitions. The company’s next test is whether that cash can translate into stronger platform growth.
Sophie Babbage
Sophie Babbage
28 Oct 2026
Audeara has moved two AI noise reduction licensing programs into commercial production, helping lift quarterly revenue 37.7% while initial orders remain modest. The milestone arrives alongside A$247,000 in cash, a A$1.292 million operating outflow and a pending A$505,000 placement tranche.
Victor Sage
Victor Sage
28 Oct 2026
LTR Pharma has moved ROXUS from signed US commercial agreements to its first fulfilled patient-specific prescriptions, while SPONTAN’s final Phase II report completes the pharmacokinetic dataset agreed with the FDA. The company ended September with A$18.2 million in cash and no debt.
Victor Sage
Victor Sage
28 Oct 2026
Amplia Therapeutics is preparing the next stage of narmafotinib’s pancreatic cancer development as its ACCENT trial nears completion and a Lilly collaboration broadens the drug’s potential into lung cancer. The biotech ended September with $20.8 million in cash, rising to $25.6 million pro forma after an October R&D tax refund.
Victor Sage
Victor Sage
28 Oct 2026
Neurotech International has dosed the first patient in its pivotal Phase 3 trial of NTI164, with all six Australian sites now active and up to 200 children planned for enrolment. The milestone sits alongside FDA clearance and fresh funding, but quarter-end cash covered only 1.24 quarters of historical operating outflows.
Ada Torres
Ada Torres
28 Oct 2026
Clever Culture Systems has fully invoiced three APAS Independence sales in the first quarter of FY27 and expects customer commitments to lift first-half sales and evaluations to eight instruments. A new paid evaluation with a Top-20 pharmaceutical company could expand its base of major drugmakers to nine, although several milestones remain prospective.
Victor Sage
Victor Sage
28 Oct 2026
Entropy Neurodynamics says all six patients in its early Phase 2 binge eating disorder cohort retained clinically meaningful improvement 12 weeks after treatment. The company is now widening TRP-8803’s development program while operating with $3.626 million in cash and an undrawn $2.6 million facility.
Ada Torres
Ada Torres
28 Oct 2026

Browse the archive

Full archive